Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Autor: T. C. Schneider, D. de Wit, T. P. Links, N. P. van Erp, J. J. M. van der Hoeven, H. Gelderblom, T. van Wezel, R. van Eijk, H. Morreau, H. J. Guchelaar, E. Kapiteijn

Publikováno v: International Journal of Endocrinology, Vol 2015 (2015)

Objective. Until recently, advanced medullary thyroid cancer (MTC) had few treatment options except surgery. The mTOR inhibitor everolimus has shown encouraging results in neuroendocrine tumors. As part of a prospective phase II study, we analyzed th

Externí odkaz: https://doaj.org/article/cfa67ea0c7d54ce4ae61aa60db8aa78c

Unintentional combining enzalutamide with a moderate CYP2C8 inhibitor in a patient with metastatic castration-resistant prostate cancer: a case report

Autor: S H, Verhulst, E, Boerrigter, S, Ras, N P, van Erp, P, Hamberg

Publikováno v: Cancer chemotherapy and pharmacology. 89(4)

Enzalutamide, registered for the treatment of metastatic castration-resistant prostate cancer (mCRPC), is an inducer of multiple CYP-enzymes. Enzalutamide itself is mainly converted by CYP2C8 to the active metabolite N-desmethylenzalutamide (NDME). D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8eae7c100f5309020d5c9d658794c443
https://pubmed.ncbi.nlm.nih.gov/35059789

Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma

Autor: M. van den Heuvel, J. Derijks, David M. Burger, N. P. van Erp, R. ter Heine, E.C.A. van den Hombergh, N. de Rouw, Sander Croes

Publikováno v: Therapeutic Drug Monitoring, 42(1), 146-150. LIPPINCOTT WILLIAMS & WILKINS
Therapeutic Drug Monitoring, 42, 146-150
Therapeutic Drug Monitoring, 42, 1, pp. 146-150

Item does not contain fulltext BACKGROUND: Pemetrexed is an antifolate cytostatic drug that targets multiple enzymes involved in folate biosynthesis and is indicated for treatment of non-small-cell lung cancer and malignant pleural mesothelioma. As e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05053b3c10b31fdea59c726869a88756
https://cris.maastrichtuniversity.nl/en/publications/28aeba94-d2f3-493b-b54e-7d79aec0b55b

Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer

Autor: Sander Croes, Y. M. de Beer, Roger J. M. Brüggemann, Lotte M. Knapen, Annelieke E.C.A.B. Willemsen, N. P. van Erp, C.M.L. van Herpen

Publikováno v: European Journal of Clinical Pharmacology
European Journal of Clinical Pharmacology, 74, 465-471
European Journal of Clinical Pharmacology, 74(4), 465-471. Springer
European Journal of Clinical Pharmacology, 74, 4, pp. 465-471

Purpose Everolimus treatment is seriously hampered by its toxicity profile. As a relationship between everolimus exposure and effectiveness and toxicity has been established, early and ongoing concentration measurement can be key to individualize the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34fcd9ad4d61f32bb0698524ed7784e3
https://doi.org/10.1007/s00228-017-2394-0

537P-SC Exposure-response analysis of cabozantinib in patients with metastatic renal cell cancer treated in routine care

Autor: Sasja F. Mulder, Stefanie L. Groenland, C.M.L. van Herpen, Dirk Jan A.R. Moes, N. P. van Erp, T. van der Hulle, Stefanie D. Krens, Ingrid M.E. Desar, Neeltje Steeghs

Publikováno v: Annals of Oncology. 32:S602

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ef2610a76000d37c0cded8397feac20
https://doi.org/10.1016/j.annonc.2021.08.1059